Corporate Information

• Novakand Pharma provides an update on the ongoing reverse take over process

  9 October 2025

• Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board

  23 September 2025

• Kancera AB changes name to Novakand Pharma AB

  22 September 2025

• Kancera initiates process to seek stakeholders for a reverse take over

  18 September 2025

• Kancera terminates letter of intent with Recardio

  12 August 2025

• Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145

  16 June 2025

• Kancera reports positive top-line results from the KANDOVA study

  13 June 2025

• Kancera reports positive outcome of pre-IND meeting with FDA

  5 June 2025

• Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program

  20 May 2025

• Kancera reports Last Patient Last Visit in the KANDOVA study

  8 April 2025